These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15332589)

  • 21. Cardiovascular remodeling and its correction: toward a comprehensive strategy.
    Bühler FR; Laragh JH; Holzgreve H
    Am J Med; 1993 Apr; 94(4A):1S-3S. PubMed ID: 8488850
    [No Abstract]   [Full Text] [Related]  

  • 22. The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases.
    Gavras H
    N Engl J Med; 1988 Dec; 319(23):1541-3. PubMed ID: 3185679
    [No Abstract]   [Full Text] [Related]  

  • 23. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA
    Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of angiotensin-converting enzyme inhibitors in the therapy of cardiovascular disease: an overview.
    Chobanian A
    Angiology; 1989 Apr; 40(4 Pt 2):331-4. PubMed ID: 2705642
    [No Abstract]   [Full Text] [Related]  

  • 25. Evolving role of angiotensin-converting enzyme inhibitors in cardiovascular therapy. Second International Symposium on Cilazapril. February 9 to 11, 1989, Basel, Switzerland. Proceedings.
    Am J Med; 1989 Dec; 87(6B):1S-99S. PubMed ID: 2532456
    [No Abstract]   [Full Text] [Related]  

  • 26. Renin report: spotlight on Renin: therapeutic opportunities for Renin inhibitors.
    Hollenberg NK;
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):107-9. PubMed ID: 16470491
    [No Abstract]   [Full Text] [Related]  

  • 27. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
    Böhm M
    Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Influence of ACE inhibitors and fibrates on endothelial function].
    Januszewicz A
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II60-4. PubMed ID: 19813338
    [No Abstract]   [Full Text] [Related]  

  • 29. Endothelin-converting enzyme inhibitors: their application in cardiovascular diseases.
    Cerdeira AS; Brás-Silva C; Leite-Moreira AF
    Rev Port Cardiol; 2008 Mar; 27(3):385-408. PubMed ID: 18551924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolongation of life with angiotensin converting enzyme inhibitor therapy.
    Torp-Pedersen C; Køber L
    Eur Heart J; 2000 Apr; 21(8):597-8. PubMed ID: 10731392
    [No Abstract]   [Full Text] [Related]  

  • 33. Angiotensin-converting enzyme and vascular remodeling.
    Heeneman S; Sluimer JC; Daemen MJ
    Circ Res; 2007 Aug; 101(5):441-54. PubMed ID: 17761934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Subclinical albuminuria, microalbuminuria and proteinuria--accepted cardiovascular risk markers?].
    Schmieder RE; Schrader J; Zidek W; Tebbe U; Bramlage P; Paar WD; Böhm M
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2665-71. PubMed ID: 17109277
    [No Abstract]   [Full Text] [Related]  

  • 37. [Efficacy of a new ACE inhibitor zofenopril (zocardis) in cardiovascular diseases].
    Ivleva AIa
    Ter Arkh; 2006; 78(8):89-93. PubMed ID: 17078226
    [No Abstract]   [Full Text] [Related]  

  • 38. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
    Ferrari R; Ambrosio G; Chiariello M
    Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511
    [No Abstract]   [Full Text] [Related]  

  • 39. Moving beyond angiotensin II to also target aldosterone?
    Little WC; Kirkman PM
    J Am Coll Cardiol; 2009 Aug; 54(6):513-4. PubMed ID: 19643311
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanisms of ET-1-induced endothelial dysfunction.
    Iglarz M; Clozel M
    J Cardiovasc Pharmacol; 2007 Dec; 50(6):621-8. PubMed ID: 18091577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.